Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

News from 31st SGO: excellent results obtained with OvaRex in selected heavily pretreated patients

Feb. 9, 2000

Two additional U.S. patents allowed for Maxamine technology

Feb. 3, 2000

Biomira reports survival data for therapeutic cancer vaccine

Jan. 31, 2000

Progenics receives payment from BMS for cancer vaccine collaboration

Jan. 31, 2000

Immunomedics reports clinical findings for cancer therapeutic

Jan. 28, 2000

Biomira initiates next stage of phase II testing of BLP25/liposomal IL-2

Jan. 26, 2000

Neurocrine Biosciences updates clinical progress with IL-4 fusion toxin

Jan. 21, 2000

Avax Technologies' O-Vax IND accepted

Jan. 19, 2000

Oxford BioMedica acquires novel antibody technology

Jan. 17, 2000

AltaRex in-licenses antibody from NIH for AIT platform

Jan. 14, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...